Perspectives on Metallo-β-Lactamase Inhibitors: Challenges and Implications of Metallo-β-Lactamase Variants
Abstract
No Abstract No Abstract No Abstract.
1. Papp-Wallace KM, Endimiani A, Taracila MA, et al (2011). Carbapenems: past, present, and future. Antimicrob Agents Chemother, 55(11):4943- 4960.
2. Mojica MF, Rossi MA, Vila AJ, et al (2022). The urgent need for metallo-β-lactamase inhibitors: an unattended global threat. Lancet Infect Dis, 22(1):e28-e34.
3. Naas T, Oueslati S, Bonnin RA, et al (2017). Beta- lactamase database (BLDB) - structure and function. J Enzyme Inhib Med Chem, 32(1):917-919.
4. Yang Y, Yan YH, Schofield CJ, et al (2023). Metallo-β-lactamase-mediated antimicrobial resistance and progress in inhibitor discovery. Trends Microbiol, 31(7):735-748.
5. Liu B, Trout REL, Chu GH, et al (2020). Discovery of taniborbactam (VNRX-5133): a broad-spectrum serine- and metallo-β- lactamase inhibitor for carbapenem-resistant bacterial infections. J Med Chem, 63(6):2789- 2801.
6. Karlowsky JA, Hackel MA, Wise MG, et al (2023). In vitro activity of cefepimetaniborbactam and comparators against clinical isolates of Gram-negative Bacilli from 2018 to 2020: results from the global evaluation of antimicrobial resistance via surveillance (GEARS) program. Antimicrob Agents Chemother, 67(1):e0128122.
7. Le Terrier C, Gruenig V, Fournier C, et al (2023). NDM-9 resistance to taniborbactam. Lancet Infect Dis, 23(4):401-402.
8. Wang X, Li H, Zhao C, et al (2014). Novel NDM-9 metallo-β-lactamase identified from a ST107 Klebsiella pneumoniae strain isolated in China. Int J Antimicrob Agents, 44(1):90-91.
2. Mojica MF, Rossi MA, Vila AJ, et al (2022). The urgent need for metallo-β-lactamase inhibitors: an unattended global threat. Lancet Infect Dis, 22(1):e28-e34.
3. Naas T, Oueslati S, Bonnin RA, et al (2017). Beta- lactamase database (BLDB) - structure and function. J Enzyme Inhib Med Chem, 32(1):917-919.
4. Yang Y, Yan YH, Schofield CJ, et al (2023). Metallo-β-lactamase-mediated antimicrobial resistance and progress in inhibitor discovery. Trends Microbiol, 31(7):735-748.
5. Liu B, Trout REL, Chu GH, et al (2020). Discovery of taniborbactam (VNRX-5133): a broad-spectrum serine- and metallo-β- lactamase inhibitor for carbapenem-resistant bacterial infections. J Med Chem, 63(6):2789- 2801.
6. Karlowsky JA, Hackel MA, Wise MG, et al (2023). In vitro activity of cefepimetaniborbactam and comparators against clinical isolates of Gram-negative Bacilli from 2018 to 2020: results from the global evaluation of antimicrobial resistance via surveillance (GEARS) program. Antimicrob Agents Chemother, 67(1):e0128122.
7. Le Terrier C, Gruenig V, Fournier C, et al (2023). NDM-9 resistance to taniborbactam. Lancet Infect Dis, 23(4):401-402.
8. Wang X, Li H, Zhao C, et al (2014). Novel NDM-9 metallo-β-lactamase identified from a ST107 Klebsiella pneumoniae strain isolated in China. Int J Antimicrob Agents, 44(1):90-91.
| Files | ||
| Issue | Vol 53 No 10 (2024) | |
| Section | Letter to the Editor | |
| DOI | https://doi.org/10.18502/ijph.v53i10.16729 | |
| Keywords | ||
| No Keywords No Keyword | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Lee JH, Kim D-W, Lee SH. Perspectives on Metallo-β-Lactamase Inhibitors: Challenges and Implications of Metallo-β-Lactamase Variants. Iran J Public Health. 2024;53(10):2389-2391.
